Table 1 Responders versus non responders
From: Impact of contractile reserve on acute response to cardiac resynchronization therapy
Variables | Responders (n = 25, 49%) | Non Responders (n = 26, 51%) | p |
|---|---|---|---|
Age, years | 71 ± 8 | 69 ± 9 | NS |
Male, n (%) | 15 (60) | 17 (65) | NS |
Ischemic cardiomyopathy, n (%) | 15 (60) | 19 (73) | NS |
QRS duration, ms | 154 ± 24 | 169 ± 25 | NS |
Diuretic, n (%) | 19 (76) | 23 (88) | NS |
β-Blockers, n (%) | 22 (88) | 22 (85) | NS |
ACEi, n (%) | 19 (76) | 22 (85) | NS |
AR Blockers, n (%) | 3 (12) | 2 (8) | NS |
Spironolactone, n (%) | 9 (36) | 14 (54) | NS |
LV-RV dyssynchrony, ms | 54 ± 16 | 50 ± 17 | NS |
LV dispersion, ms | 109 ± 44 | 61 ± 35 | <0.0001 |
Mitral effective regurgitant orifice, mm2 | 22 ± 11 | 15 ± 9 | 0.018 |
LV end-diastolic volume, ml | 175 ± 34 | 193 ± 42 | NS |
LV end-systolic volume, ml | 128 ± 26 | 139 ± 35 | NS |
LV ejection fraction, % | 27.1 ± 5.0 | 27.7 ± 5.3 | NS |
LV ejection fraction at exer., % | 35 ± 5.7 | 31 ± 5.3 | 0.03 |
LV ejection fraction diff., % | 8.4 ± 2.4 | 4.2 ± 2.6 | <0.0001 |
Wall motion score index | 2.2 ± 0.27 | 2.28 ± 0.35 | NS |
Wall motion score index at exer | 1.86 ± 0.34 | 2.15 ± 0.34 | 0.0033 |
Wall motion score index diff | -0.3 ± 0.26 | -0.13 ± 0.21 | 0.013 |
Strain target LV lead wall, % | 15 ± 2.8 | 10.2 ± 6.3 | 0.0007 |
Strain target LV lead wall at exer, % | 19.3 ± 2.4 | 10.7 ± 8.5 | <0.0001 |
Strain target LV lead wall diff., % | 4.2 ± 1.6 | 0.44 ± 3.5 | <0.0001 |